Pharmaceutical Research Overview
LQuin 500mg by Cipla is a pharmaceutical-grade levofloxacin preparation designed for laboratory research investigating fluoroquinolone antimicrobial mechanisms. As a third-generation fluoroquinolone antibiotic, this compound enables researchers to study bacterial DNA gyrase inhibition pathways and resistance development mechanisms in controlled laboratory environments. Manufactured by Cipla, this preparation provides researchers at Stroid UK Shop with access to high-quality reference material for antimicrobial studies.
Laboratory Research Applications
Research scientists examine LQuin 500mg to investigate fluoroquinolone mechanisms of action against gram-positive and gram-negative bacterial strains. Laboratory studies focus on DNA gyrase and topoisomerase IV inhibition pathways, evaluating how levofloxacin disrupts bacterial DNA replication processes. Microbiologists analyse this compound’s broad-spectrum activity profile and study resistance mutation patterns in clinical isolates. Pharmaceutical researchers investigate bioavailability parameters and pharmacokinetic properties in controlled laboratory settings. Academic institutions examine this preparation alongside other levofloxacin research compounds to advance antimicrobial therapy understanding. Research applications extend to investigating combination therapy approaches and synergistic effects with other antimicrobial agents. Scientists study the compound’s activity against biofilm-forming bacteria and intracellular pathogen models. Laboratory protocols examine minimum inhibitory concentration (MIC) determinations across various bacterial species. Researchers evaluate this compound’s stability under different storage conditions and pH environments. Comparative studies investigate efficacy differences between levofloxacin formulations from different manufacturers. Research teams examine the compound’s penetration characteristics in laboratory tissue models. Scientists study molecular interactions between levofloxacin and bacterial target enzymes using this preparation. Advanced research includes investigating novel delivery mechanisms and formulation approaches. Laboratory studies examine the compound’s effects on bacterial quorum sensing pathways. Research applications include studying resistance prevention strategies and combination antimicrobial protocols. Scientists investigate this preparation’s activity against emerging multi-drug resistant bacterial strains. Beyond traditional antimicrobial research, scientists examine potential applications in studying bacterial communication networks. Research extends to investigating the compound’s immunomodulatory effects in laboratory cell culture systems. Scientists analyse this preparation alongside selective androgen receptor modulators and research peptides in comprehensive laboratory studies examining drug interactions and cellular pathway modulation.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Levofloxacin |
| Strength | 500mg |
| Manufacturer | Cipla |
| Form | Pharmaceutical tablets |
| CAS Number | 100986-85-4 |
| Molecular Formula | C₁₈H₂₀FN₃O₄ |
| Molecular Weight | 361.37 g/mol |
| Storage | Room temperature, dry conditions |
| Shelf Life | As per manufacturer specifications |
Research Compliance
LQuin 500mg is supplied exclusively for in-vitro research purposes and laboratory studies. This pharmaceutical preparation is not intended for human consumption, therapeutic use, or clinical applications. Researchers must maintain appropriate laboratory safety protocols when handling this antimicrobial compound. All studies should comply with institutional biosafety guidelines and antimicrobial research regulations.
